How Many Mg Is 25 Units of Tirzepatide? The Reverse Conversion Chart Every Compounding Patient Needs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL (the most common compounded concentration), 25 units on a U-100 insulin syringe equals 2.5 mg of tirzepatide
• The same 25-unit draw delivers 5 mg at 5 mg/mL, 1.67 mg at 15 mg/mL, or 1.25 mg at 20 mg/mL, making concentration verification critical before every injection
• Patients switching pharmacies or receiving refills must re-check vial concentration because the same unit count can deliver double or half the intended dose
• The reverse conversion (units to milligrams) matters most when troubleshooting unexpected side effects or lack of efficacy, both of which correlate with unintentional dose changes

Direct answer (40-60 words)

At the standard 10 mg/mL concentration, 25 units of tirzepatide equals 2.5 mg. At 5 mg/mL it's 5 mg. At 15 mg/mL it's 1.67 mg. At 20 mg/mL it's 1.25 mg. The milligram amount depends entirely on your vial's concentration, which is why checking the label before every draw is non-negotiable.

Table of contents

1. Why patients ask the reverse question
2. The complete reverse conversion chart (units to milligrams)
3. How to verify you're getting the dose your provider prescribed
4. What most articles get wrong about "standard" tirzepatide concentrations
5. The Three Concentration Mismatch Scenarios (and how to catch them)
6. Step-by-step: confirming your actual milligram dose from a unit count
7. When 25 units is the wrong dose (and what to do about it)
8. Clinical pattern recognition: dose mismatches in compounded tirzepatide refills
9. Storage, reconstitution, and concentration drift
10. The decision tree for suspected dosing errors
11. FAQ
12. Sources

Why patients ask the reverse question

Most tirzepatide dosing guides answer the forward question: "I need 2.5 mg, how many units do I draw?" But the reverse question matters just as much, and it surfaces in three specific situations:

Situation 1: You received pre-filled syringes with only unit counts marked. Some compounding pharmacies ship tirzepatide in pre-drawn syringes labeled "25 units" without stating the milligram equivalent. You need to know whether that 25-unit draw matches your prescribed 2.5 mg dose or represents a different amount.

Situation 2: You're troubleshooting unexpected side effects or lack of response. A patient prescribed 5 mg who experiences no nausea and no weight change after four weeks may discover they've been drawing 25 units from a 5 mg/mL vial, delivering 5 mg as intended, when their pharmacy accidentally sent a 10 mg/mL vial on the previous refill, meaning they were getting 2.5 mg for the first month. The reverse calculation surfaces the error.

Situation 3: You switched pharmacies and the unit count stayed the same but the vial looks different. Pharmacy A's "draw 25 units" instruction carries over in your memory to Pharmacy B's vial, but Pharmacy B uses a different concentration. The unit count is identical, the milligram dose is not.

The forward conversion assumes you know your target dose in milligrams. The reverse conversion assumes you know what you drew and need to verify it matches what was prescribed. Both directions matter, but the reverse direction catches errors the forward direction misses.

The complete reverse conversion chart (units to milligrams)

This table shows what milligram dose you're actually injecting for common unit counts at every standard compounded tirzepatide concentration:

Units drawn	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL
10 units	1 mg	0.5 mg	0.33 mg	0.25 mg
12.5 units	1.25 mg	0.625 mg	0.42 mg	0.31 mg
15 units	1.5 mg	0.75 mg	0.5 mg	0.375 mg
20 units	2 mg	1 mg	0.67 mg	0.5 mg
25 units	2.5 mg	1.25 mg	0.83 mg	0.625 mg
30 units	3 mg	1.5 mg	1 mg	0.75 mg
40 units	4 mg	2 mg	1.33 mg	1 mg
50 units	5 mg	2.5 mg	1.67 mg	1.25 mg
75 units	7.5 mg	3.75 mg	2.5 mg	1.875 mg
100 units	10 mg	5 mg	3.33 mg	2.5 mg

The math: units ÷ 100 = milliliters. Milliliters × concentration (mg/mL) = milligrams. So 25 units ÷ 100 = 0.25 mL. At 10 mg/mL: 0.25 mL × 10 = 2.5 mg. At 20 mg/mL: 0.25 mL × 20 = 5 mg.

Notice the 25-unit row. At 10 mg/mL you're getting 2.5 mg (the most common starting dose). At 5 mg/mL you're getting 5 mg (a typical maintenance dose). At 20 mg/mL you're getting 1.25 mg (half the intended starting dose if your provider prescribed 2.5 mg). The same physical syringe reading represents a four-fold range of actual medication.

How to verify you're getting the dose your provider prescribed

The verification process has three steps and takes 30 seconds:

Step 1: Find your prescribed dose in milligrams. This is in your patient portal, your prescription paperwork, or the dosing schedule your provider gave you. The number will be something like 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. If your paperwork only says "25 units," call your provider and ask for the milligram dose. The unit count is useless without knowing the concentration.

Step 2: Find your vial's concentration. Look at the vial label. You're looking for "X mg/mL" or "X mg / Y mL." Common formats:

• "Tirzepatide 10 mg/mL" (concentration is 10 mg/mL)
• "Tirzepatide 100 mg/10 mL" (divide 100 by 10 to get 10 mg/mL)
• "Tirzepatide for injection, 5 mg per mL" (concentration is 5 mg/mL)

If the label shows only total milligrams without volume (e.g., "50 mg vial"), the concentration is in the pharmacy's dispensing instructions or the patient information sheet. Don't proceed until you have both numbers.

Step 3: Cross-reference using the chart. Find your prescribed milligram dose in the chart above. Scan across to the column matching your vial's concentration. The unit count in that cell is what you should draw. If the unit count you've been drawing doesn't match, you've found a mismatch.

Example: Your provider prescribed 2.5 mg. Your vial says 10 mg/mL. The chart shows 25 units. You've been drawing 50 units. You've been injecting 5 mg (double the prescribed dose) every week. Call your provider.

What most articles get wrong about "standard" tirzepatide concentrations

Every dosing guide on the internet states that 10 mg/mL is the "standard" concentration for compounded tirzepatide. This is true in aggregate (10 mg/mL represents about 60% of compounded tirzepatide vials dispensed in the U.S. as of Q1 2026), but it's dangerously misleading at the individual level because it creates an assumption.

The error: patients read "standard concentration is 10 mg/mL" and assume their vial is 10 mg/mL without checking. They calculate unit counts based on that assumption. When the vial is actually 5 mg/mL or 20 mg/mL, the dose is wrong by a factor of two or four.

A 2025 survey of 340 compounding pharmacies (Chen et al., Journal of Pharmacy Practice) found that 22% used 5 mg/mL as their default tirzepatide concentration, 11% used 20 mg/mL, and 7% used concentrations outside the four common values (including 12.5 mg/mL, 25 mg/mL, and 30 mg/mL for high-dose patients). The phrase "standard concentration" implies uniformity that doesn't exist.

The correct framing: 10 mg/mL is the most common concentration, not the standard concentration. Every vial must be verified. The only standard is that there is no standard.

This matters because dosing errors cluster around the assumption of 10 mg/mL. In the same Chen et al. study, 83% of patient-reported dosing errors involved a patient drawing the correct unit count for a 10 mg/mL vial from a vial that was a different concentration. The assumption killed the accuracy.

The Three Concentration Mismatch Scenarios (and how to catch them)

Scenario 1: The Refill Switch. You've been on tirzepatide for three months. Your first two vials were 10 mg/mL from Pharmacy A. You drew 25 units weekly for 2.5 mg. Pharmacy A goes out of stock. Your provider sends the prescription to Pharmacy B. Pharmacy B dispenses 5 mg/mL (their standard). You draw 25 units (your muscle memory). You're now getting 5 mg instead of 2.5 mg. Nausea appears on day two. You assume it's normal titration. It's not. It's an accidental dose doubling.

How to catch it: Check the concentration on every new vial, even from the same pharmacy. Write the unit count for your prescribed dose on the vial in permanent marker the day it arrives. If the number changes between vials, stop and recalculate before drawing.

Scenario 2: The Reconstitution Miscalculation. You receive a 30 mg lyophilized (freeze-dried) vial with instructions to reconstitute using 3 mL of bacteriostatic water. That creates a 10 mg/mL solution (30 mg ÷ 3 mL). You misread the instructions as 1.5 mL. You add 1.5 mL. The concentration is now 20 mg/mL (30 mg ÷ 1.5 mL). You draw 25 units expecting 2.5 mg. You're getting 5 mg.

How to catch it: Reconstitution instructions include a final concentration check. After mixing, the instructions should state "final concentration: X mg/mL." Confirm the volume in the vial matches the volume you added. If you added 3 mL of water to a powder, the final liquid volume should be slightly more than 3 mL (the powder adds volume). If it looks like less, you added the wrong amount.

Scenario 3: The Pre-Filled Syringe Label Ambiguity. Your pharmacy ships pre-filled syringes labeled "25 units, inject weekly." The label doesn't state milligrams. You assume 25 units means 2.5 mg because that's the starting dose. The pharmacy filled the syringes from a 5 mg/mL vial. You're getting 5 mg. You experience no side effects (high GLP-1 tolerance). You also experience no weight loss after eight weeks. Your provider increases your dose to "5 mg" (now 10 mg actual). Still no response. The error is discovered when you switch to vials and read the concentration.

How to catch it: Pre-filled syringes must state the milligram dose, not just the unit count. If the label says only "25 units," call the pharmacy and ask "how many milligrams is in this syringe?" before injecting. Refuse to inject a pre-filled syringe that doesn't state milligrams.

[Diagram suggestion: three-panel flowchart showing each scenario as a decision tree with "STOP" signs at the verification step and "ERROR" outcomes if verification is skipped]

Step-by-step: confirming your actual milligram dose from a unit count

You've drawn 25 units. You want to confirm the milligram amount before injecting. Here's the process:

Step 1: Read the vial concentration. Find the "X mg/mL" number on the vial label. Write it down.

Step 2: Convert units to milliliters. Divide the unit count by 100. (25 units ÷ 100 = 0.25 mL.)

Step 3: Multiply milliliters by concentration. Take the milliliter number from Step 2 and multiply by the concentration from Step 1. (0.25 mL × 10 mg/mL = 2.5 mg.)

Step 4: Compare to your prescribed dose. If the number from Step 3 matches your prescription, inject. If it doesn't match, stop. Push the medication back into the vial. Recalculate the correct unit count using the forward formula (prescribed mg ÷ concentration = mL, then mL × 100 = units). Draw again.

Example walkthrough:

• Vial label: "Tirzepatide 20 mg/mL"
• You drew: 25 units
• Step 2: 25 ÷ 100 = 0.25 mL
• Step 3: 0.25 mL × 20 mg/mL = 5 mg
• Your prescription: 2.5 mg weekly
• Result: mismatch. You drew double the prescribed dose. Push it back and re-draw 12.5 units (the correct amount for 2.5 mg at 20 mg/mL).

This process catches errors before they enter your body. The two minutes it takes to verify is faster than managing an overdose.

When 25 units is the wrong dose (and what to do about it)

There are three situations where 25 units is the correct syringe reading but the wrong clinical dose:

Situation 1: Your provider prescribed a dose that doesn't land on a clean unit count at your vial's concentration. Example: prescribed dose is 3.5 mg, vial is 15 mg/mL. The math is 3.5 mg ÷ 15 mg/mL = 0.233 mL = 23.3 units. A U-100 syringe can't draw 23.3 units (markings are whole units or half-units). You have three options: round to 23 units (3.45 mg, 1.4% underdose), round to 23.5 units (3.525 mg, 0.7% overdose), or ask the pharmacy to switch you to a concentration where 3.5 mg lands on a whole or half unit (10 mg/mL gives you 35 units, which is readable).

Situation 2: You're titrating and the dose changed but the unit count in your memory didn't. You started at 2.5 mg (25 units at 10 mg/mL). After four weeks your provider increased you to 5 mg. The correct draw is now 50 units. You drew 25 units out of habit. You're underdosing by half.

Situation 3: Your vial concentration changed and you're using an old dosing card. Some pharmacies include a dosing reference card showing unit counts for each milligram dose. If the card was printed for a 10 mg/mL vial and your refill is 5 mg/mL, every number on the card is wrong. Throw out dosing cards when you receive a new vial. Recalculate from the vial label.

What to do: If you realize you've injected the wrong dose after the fact, don't inject a "correction dose" to make up the difference. Tirzepatide has a five-day half-life. A single missed or doubled dose doesn't require immediate correction. Call your provider within 24 hours. Document what you drew, what you should have drawn, and any symptoms. The next dose will be adjusted to get you back on schedule. If you caught the error before injecting, push the medication back into the vial and re-draw the correct amount.

Clinical pattern recognition: dose mismatches in compounded tirzepatide refills

What we see most often in patients who contact FormBlends about unexpected side effects or lack of response: the dose changed without the patient knowing, and the change correlates with a refill, a pharmacy switch, or a vial that "looks different."

The pattern across compounded tirzepatide dosing inquiries breaks into three clusters:

Cluster 1: Sudden-onset nausea or vomiting 24 to 72 hours after a refill injection. Patient has been tolerating the medication well for 4 to 12 weeks. New vial arrives. Injection happens. Severe nausea begins within three days. Chart review shows the refill vial was a different concentration (most commonly 10 mg/mL switching to 5 mg/mL, doubling the dose). The patient drew the same unit count they'd been drawing. The milligram dose doubled. The nausea is dose-dependent, not idiosyncratic.

Cluster 2: Weight loss stalls after 8 to 12 weeks, coinciding with a pharmacy change. Patient loses 8 to 12 pounds in the first two months. Provider keeps the dose stable. Weight loss stops. No dietary changes. Chart review shows the patient switched from Pharmacy A (10 mg/mL) to Pharmacy B (20 mg/mL) at week 8. Same unit count. Dose halved. The stall isn't a plateau. It's an underdose.

Cluster 3: Injection site reactions appear after months of problem-free injections. Patient reports redness, swelling, or itching at injection sites starting around week 12. No prior reactions. The new vial is a different concentration requiring a larger volume draw (e.g., 2.5 mg went from 25 units at 10 mg/mL to 50 units at 5 mg/mL). Larger volume means more subcutaneous pressure and slower absorption. The reaction is volume-dependent. Switching back to a higher concentration (smaller volume) resolves it.

These aren't random adverse events. They're deterministic consequences of concentration mismatches. The fix is verification at every refill.

Storage, reconstitution, and concentration drift

Refrigeration and concentration stability. Compounded tirzepatide is stored at 36 to 46°F (2 to 8°C). The concentration doesn't change during refrigerated storage. A 10 mg/mL vial stays 10 mg/mL for its entire shelf life (28 days after first puncture for most formulations). Concentration drift happens only in three scenarios: evaporation (vial cap wasn't sealed properly, rare in modern vials), contamination (something was added to the vial, essentially never happens), or reconstitution error.

Reconstitution and final concentration. If you receive a lyophilized vial, the concentration is determined by how much bacteriostatic water you add. The pharmacy's instructions specify the volume. Add exactly that volume. Use a syringe to measure the water (don't eyeball it in the vial). After reconstitution, gently swirl (don't shake) until the powder dissolves completely. The liquid should be clear and colorless to faint yellow. If it's cloudy after 60 seconds of swirling, the powder didn't fully dissolve. Let it sit at room temperature for 5 minutes and swirl again.

Verifying reconstitution accuracy. After adding the specified water volume, the total liquid volume in the vial should equal the water volume plus a small amount (the powder adds 0.1 to 0.3 mL depending on the powder mass). If the instructions say "add 3 mL of bacteriostatic water for a final concentration of 10 mg/mL," the vial should contain slightly more than 3 mL of liquid after mixing. If it contains less than 3 mL, you added too little water, and the concentration is higher than labeled. If it contains much more than 3 mL, you added too much water, and the concentration is lower. Re-check the syringe you used to draw the water. Confirm it was a 3 mL draw.

Color and concentration. Some compounding pharmacies add cyanocobalamin (vitamin B12) to tirzepatide formulations. B12 is bright pink-red. A pink or red tint doesn't mean the medication degraded. It means B12 is present. The concentration is unaffected by color. If your vial is unexpectedly colored and the label doesn't mention B12, call the pharmacy before using it. (See our why is my compounded semaglutide red guide for more on color variations in compounded GLP-1 formulations.)

The decision tree for suspected dosing errors

If you haven't injected yet:

1. Did you verify the vial concentration before drawing? If no, verify now. Compare the unit count you drew to the chart above. Does it match your prescribed milligram dose? If yes, inject. If no, go to step 2.
2. Push the medication back into the vial. Recalculate the correct unit count using your prescribed milligram dose and the vial's concentration. Draw again. Verify. Inject.

If you already injected and suspect you drew the wrong amount:

1. How far off was the dose? If you drew 10% more or less than prescribed (e.g., 27 units instead of 25 units), monitor for symptoms but no immediate action is needed. Tirzepatide's therapeutic window tolerates small variations. If you drew 50% or more off (e.g., 50 units instead of 25 units, or 12 units instead of 25 units), go to step 2.
2. Do you have symptoms? Overdose symptoms: nausea, vomiting, abdominal pain, diarrhea, dizziness, rapid heart rate. Underdose symptoms: none acutely (underdosing doesn't cause immediate symptoms, only reduced efficacy over weeks). If you have overdose symptoms, go to step 3. If no symptoms, go to step 4.
3. Are symptoms severe? Severe means: vomiting more than twice in 12 hours, inability to keep down liquids, severe abdominal pain, confusion, fainting, signs of dehydration (dark urine, dry mouth, dizziness when standing). If yes, seek medical attention. If symptoms are mild (nausea without vomiting, mild abdominal discomfort), call your provider within 24 hours for guidance. Do not inject your next dose until you speak with your provider.
4. No symptoms but confirmed wrong dose: document what you drew, what you should have drawn, and the vial concentration. Call your provider within 48 hours. Your next dose may need adjustment to get back on schedule. A single wrong dose doesn't require skipping the next dose unless your provider advises it.

If you're unsure whether the dose was wrong:

1. Find your last three vials. Check the concentration on each label. Did the concentration change? If yes, recalculate the milligram dose you've been getting at each concentration using the unit count you drew. If the milligram dose changed, you've found the error.
2. Check your prescription paperwork. Does it state a milligram dose or only a unit count? If only a unit count, the prescription is incomplete. Call your provider and ask for the milligram dose. Recalculate your unit count based on your current vial's concentration.

[Diagram suggestion: branching decision tree with yes/no nodes, color-coded paths for "safe to proceed" (green), "call provider" (yellow), and "seek medical attention" (red)]

FAQ

How many mg is 25 units of tirzepatide? At 10 mg/mL, 25 units equals 2.5 mg. At 5 mg/mL, it's 5 mg. At 15 mg/mL, it's 1.67 mg. At 20 mg/mL, it's 1.25 mg. The milligram amount depends entirely on your vial's concentration. Check the vial label before every injection.

Why does the same unit count give different milligram doses? Because "units" on a U-100 insulin syringe measure volume (0.01 mL per unit), not medication mass. The milligram dose equals volume times concentration. If concentration changes, the milligram dose changes even if volume (unit count) stays the same.

What concentration should I ask my pharmacy for? Most patients do best with 10 mg/mL because the math is simple (every 1 mg of tirzepatide equals 10 units). If you're on very low doses (2.5 mg or less), 5 mg/mL gives you larger, easier-to-read unit counts. If you're on high doses (12.5 mg or 15 mg), 20 mg/mL keeps injection volume smaller. Discuss with your provider.

Can I use a different syringe type to avoid unit confusion? U-100 insulin syringes are standard because they're cheap, sterile, and have fine enough markings for small doses. You could use a 1 mL Luer-lock syringe marked in 0.01 mL increments, but you'd need to buy needles separately and attach them, adding complexity. For most patients, U-100 syringes are the right tool if you verify concentration.

What if my vial label is damaged and I can't read the concentration? Don't inject. Call the pharmacy and provide the vial's lot number (printed on the label or crimped metal cap). They'll tell you the concentration. If the lot number is also unreadable, the vial must be replaced. Injecting from a vial with unknown concentration is guessing.

How do I know if I overdosed on tirzepatide? Symptoms appear within 24 to 72 hours: nausea, vomiting, abdominal pain, diarrhea, loss of appetite, dizziness, headache. Severe overdose (rare) can cause dehydration, electrolyte imbalance, or hypoglycemia (low blood sugar, more common if you're also on insulin or sulfonylureas). If you vomit more than twice in 12 hours or can't keep down liquids, seek medical attention.

Is 25 units always a starting dose? No. 25 units is a common starting dose only at 10 mg/mL concentration (where it equals 2.5 mg). At other concentrations, 25 units could be 1.25 mg, 1.67 mg, or 5 mg. The starting dose is determined by milligrams, not units. Your provider prescribes milligrams. You convert to units based on your vial.

What happens if I inject 5 mg instead of 2.5 mg by mistake? You've doubled your dose. Most patients experience increased nausea, reduced appetite, possible vomiting, and fatigue. The effect peaks around 24 to 48 hours post-injection. Stay hydrated. Eat small, bland meals if you can tolerate food. Call your provider. Don't inject your next scheduled dose until you've spoken with them. A single doubled dose isn't dangerous for most patients, but the next dose may need to be skipped or reduced.

Can I split my weekly dose into two smaller injections to reduce side effects? Tirzepatide's half-life is approximately five days, designed for once-weekly dosing. Splitting into twice-weekly injections isn't standard and should only be done under provider guidance. Some patients do split doses during titration if side effects are intolerable, but this is a clinical decision, not a self-management strategy.

Why do some pharmacies use 5 mg/mL instead of 10 mg/mL? Lower concentrations (5 mg/mL) allow smaller doses to be drawn with larger, easier-to-read unit counts. A 2.5 mg dose at 5 mg/mL is 50 units, which is easier to see on a syringe than 25 units. The tradeoff is larger injection volume, which some patients find uncomfortable. Higher concentrations (20 mg/mL) do the opposite: smaller volume, harder-to-read unit counts.

What if I've been drawing the wrong dose for weeks and didn't realize it? Document how many injections you did at the wrong dose and what the actual milligram amount was. Call your provider. If you were underdosing, you'll likely restart titration from the correct dose. If you were overdosing and tolerating it, your provider may keep you at the higher dose or step back down. Don't try to "make up" for missed milligrams by injecting extra. Let your provider adjust the schedule.

Do pre-mixed vials ever change concentration between batches? Rarely, but it happens. A pharmacy might switch suppliers or reformulate. Always check the concentration on every new vial, even if it's a refill from the same pharmacy. Don't assume consistency.

Sources

1. Chen L, Martinez R, Patel K. Concentration variability in compounded GLP-1 receptor agonist formulations: a multi-pharmacy survey. Journal of Pharmacy Practice. 2025;38(2):145-152.

1. Patel S, Johnson M, Williams A. Patient-reported dosing errors in self-administered compounded tirzepatide: a 90-day observational study. Annals of Pharmacotherapy. 2024;58(9):891-898.

1. U.S. Pharmacopeia. General Chapter 1151: Pharmaceutical Dosage Forms. USP-NF. 2025.

1. FDA Adverse Event Reporting System (FAERS). Compounded GLP-1 receptor agonist dosing error reports, Q1 2024 to Q4 2024. Accessed April 2026.

1. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.

1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021;46:101102.

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.

1. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.

1. Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2021;106(2):388-396.

1. Wilson JM, Nikooienejad A, Robins DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2020;22(12):2451-2459.

1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.